Stephens Inc. AR Sells 1,504 Shares of Solventum Co. (NYSE:SOLV)

Stephens Inc. AR trimmed its position in shares of Solventum Co. (NYSE:SOLV) by 22.4% during the 3rd quarter, Holdings Channel reports. The firm owned 5,222 shares of the company’s stock after selling 1,504 shares during the period. Stephens Inc. AR’s holdings in Solventum were worth $364,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. National Bank of Canada FI grew its stake in Solventum by 4.0% during the second quarter. National Bank of Canada FI now owns 6,093 shares of the company’s stock valued at $314,000 after acquiring an additional 236 shares in the last quarter. IVC Wealth Advisors LLC increased its holdings in shares of Solventum by 5.0% in the 3rd quarter. IVC Wealth Advisors LLC now owns 6,649 shares of the company’s stock worth $464,000 after buying an additional 318 shares during the last quarter. Copeland Capital Management LLC bought a new stake in shares of Solventum in the 3rd quarter worth about $26,000. Mather Group LLC. bought a new stake in shares of Solventum in the 3rd quarter worth about $27,000. Finally, Massmutual Trust Co. FSB ADV grew its holdings in Solventum by 64.9% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 1,072 shares of the company’s stock valued at $75,000 after purchasing an additional 422 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Morgan Stanley cut their price target on shares of Solventum from $70.00 to $55.00 and set an “equal weight” rating on the stock in a report on Monday, July 15th. BTIG Research assumed coverage on shares of Solventum in a report on Thursday, September 5th. They set a “neutral” rating on the stock. The Goldman Sachs Group upped their price target on shares of Solventum from $48.00 to $54.00 and gave the company a “sell” rating in a report on Monday, August 12th. Wells Fargo & Company cut their price target on shares of Solventum from $69.00 to $64.00 and set an “equal weight” rating on the stock in a report on Friday, August 9th. Finally, Stifel Nicolaus assumed coverage on shares of Solventum in a report on Tuesday, October 8th. They set a “buy” rating and a $82.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat.com, Solventum currently has an average rating of “Hold” and a consensus target price of $64.33.

Solventum Price Performance

Solventum stock opened at $75.07 on Friday. The firm has a 50-day moving average of $69.67 and a two-hundred day moving average of $61.86. Solventum Co. has a 1 year low of $47.16 and a 1 year high of $96.05. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.31 and a quick ratio of 0.96.

Solventum (NYSE:SOLV) last announced its quarterly earnings results on Thursday, August 8th. The company reported $1.56 earnings per share for the quarter, topping the consensus estimate of $1.46 by $0.10. The business had revenue of $2.08 billion during the quarter, compared to analysts’ expectations of $2.05 billion. The firm’s revenue was up .2% on a year-over-year basis. Equities analysts anticipate that Solventum Co. will post 6.38 EPS for the current fiscal year.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.